Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By Sue Sutter
  
Man climbing mountain.
Stealth faces a steep hill at the FDA cardio-renal adcomm on elamipretide. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from Rare Diseases